Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Tvardi Therapeutics (TVRD) EBITDA Margin (2016 - 2025)

Tvardi Therapeutics' EBITDA Margin history spans 13 years, with the latest figure at 190.97% for Q1 2025.

  • On a quarterly basis, EBITDA Margin rose 124355.0% to 190.97% in Q1 2025 year-over-year; TTM through Mar 2025 was 397.58%, a 32053.0% increase, with the full-year FY2024 number at 411.9%, up 14658.0% from a year prior.
  • EBITDA Margin hit 190.97% in Q1 2025 for Tvardi Therapeutics, up from 873.33% in the prior quarter.
  • Over the last five years, EBITDA Margin for TVRD hit a ceiling of 4.97% in Q3 2021 and a floor of 4109.74% in Q4 2021.
  • Historically, EBITDA Margin has averaged 813.22% across 5 years, with a median of 588.95% in 2022.
  • Biggest five-year swings in EBITDA Margin: crashed -418022bps in 2021 and later skyrocketed 319398bps in 2022.
  • Tracing TVRD's EBITDA Margin over 5 years: stood at 4109.74% in 2021, then skyrocketed by 78bps to 915.76% in 2022, then decreased by -17bps to 1070.51% in 2023, then grew by 18bps to 873.33% in 2024, then soared by 78bps to 190.97% in 2025.
  • Business Quant data shows EBITDA Margin for TVRD at 190.97% in Q1 2025, 873.33% in Q4 2024, and 215.69% in Q3 2024.